Genomma Lab Internacional. de Past Earnings Performance
Past criteria checks 2/6
Genomma Lab Internacional. de has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 4.4% per year. Genomma Lab Internacional. de's return on equity is 13.7%, and it has net margins of 9.3%.
Key information
6.82%
Earnings growth rate
7.52%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.39% |
| Revenue growth rate | 4.36% |
| Return on equity | 13.69% |
| Net Margin | 9.25% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Productivity Savings And Channel Expansion Will Support A Stronger Long Term Earnings Profile
Catalysts About Genomma Lab Internacional. de Genomma Lab Internacional.
Seasonal Volatility And Cost Cuts Will Test Margin Ambitions Yet Support A Cautious Upside View
Catalysts About Genomma Lab Internacional. de Genomma Lab Internacional.Genomma Lab Internacional. de (BMV:LABB) Has Announced A Dividend Of MX$0.20
The board of Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) has announced that it will pay a dividend of...Potential Upside For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Not Without Risk
With a price-to-earnings (or "P/E") ratio of 9.3x Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) may be sending...Genomma Lab Internacional. de (BMV:LABB) Is Paying Out A Dividend Of MX$0.20
The board of Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) has announced that it will pay a dividend of...Genomma Lab Internacional. de (BMV:LABB) Is Paying Out A Dividend Of MX$0.20
Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) has announced that it will pay a dividend of MX$0.20 per share...These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...We Think Genomma Lab Internacional. de (BMV:LABB) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Investors Appear Satisfied With Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Prospects
When close to half the companies in Mexico have price-to-earnings ratios (or "P/E's") below 11x, you may consider...Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Key Insights The projected fair value for Genomma Lab Internacional. de is Mex$21.54 based on 2 Stage Free Cash Flow to...With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For
When close to half the companies in Mexico have price-to-earnings ratios (or "P/E's") below 13x, you may consider...These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?
Key Insights Genomma Lab Internacional. de's estimated fair value is Mex$28.31 based on 2 Stage Free Cash Flow to...Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Genomma Lab Internacional. de fair value estimate is Mex$22.94...Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic
Shareholders in Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) may be thrilled to learn that the analysts have...Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts
The analysts covering Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) delivered a dose of negativity to...Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Revenue & Expenses Breakdown
How Genomma Lab Internacional. de makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 17,325 | 1,603 | 7,269 | 0 |
| 31 Dec 25 | 17,541 | 1,614 | 7,292 | 0 |
| 30 Sep 25 | 18,190 | 1,655 | 7,714 | 0 |
| 30 Jun 25 | 18,841 | 1,881 | 7,944 | 0 |
| 31 Mar 25 | 18,816 | 2,158 | 7,979 | 0 |
| 31 Dec 24 | 18,607 | 2,091 | 8,055 | 0 |
| 30 Sep 24 | 17,466 | 1,663 | 7,432 | 0 |
| 30 Jun 24 | 16,767 | 1,373 | 7,121 | 0 |
| 31 Mar 24 | 16,486 | 1,159 | 6,965 | 0 |
| 31 Dec 23 | 16,467 | 1,085 | 6,889 | 0 |
| 30 Sep 23 | 17,074 | 1,392 | 6,988 | 0 |
| 30 Jun 23 | 17,030 | 1,421 | 7,002 | 0 |
| 31 Mar 23 | 16,983 | 1,408 | 6,932 | 0 |
| 31 Dec 22 | 16,820 | 1,366 | 6,922 | 0 |
| 30 Sep 22 | 16,778 | 1,359 | 7,185 | 0 |
| 30 Jun 22 | 16,412 | 1,353 | 7,043 | 0 |
| 31 Mar 22 | 15,954 | 1,328 | 6,877 | 0 |
| 31 Dec 21 | 15,487 | 1,308 | 6,570 | 0 |
| 30 Sep 21 | 14,868 | 1,352 | 6,135 | 0 |
| 30 Jun 21 | 14,312 | 1,368 | 5,872 | 0 |
| 31 Mar 21 | 14,083 | 1,416 | 5,736 | 0 |
| 31 Dec 20 | 13,870 | 1,404 | 5,666 | 0 |
| 30 Sep 20 | 13,619 | 1,179 | 5,899 | 0 |
| 30 Jun 20 | 13,268 | 1,003 | 5,824 | 0 |
| 31 Mar 20 | 12,910 | 886 | 5,810 | 0 |
| 31 Dec 19 | 12,713 | 750 | 5,824 | 0 |
| 30 Sep 19 | 12,617 | 935 | 5,815 | 0 |
| 30 Jun 19 | 12,274 | 925 | 5,735 | 0 |
| 31 Mar 19 | 11,921 | 986 | 5,615 | 0 |
| 31 Dec 18 | 11,794 | 1,109 | 5,578 | 0 |
| 30 Sep 18 | 11,556 | 1,242 | 5,264 | 0 |
| 30 Jun 18 | 11,900 | 1,249 | 5,378 | 0 |
| 31 Mar 18 | 11,886 | 1,218 | 5,454 | 0 |
| 31 Dec 17 | 12,078 | 1,279 | 5,622 | 0 |
| 30 Sep 17 | 11,898 | 958 | 6,295 | 0 |
| 30 Jun 17 | 11,741 | 1,212 | 6,383 | 0 |
| 31 Mar 17 | 11,669 | -1,603 | 7,551 | 0 |
| 31 Dec 16 | 11,316 | -1,681 | 7,491 | 0 |
| 30 Sep 16 | 11,287 | -3,447 | 8,438 | 0 |
| 30 Jun 16 | 10,988 | -3,759 | 8,363 | 0 |
| 31 Mar 16 | 11,125 | -895 | 7,325 | 0 |
| 31 Dec 15 | 11,042 | -1,137 | 7,334 | 0 |
| 30 Sep 15 | 11,211 | 1,109 | 5,791 | 0 |
| 30 Jun 15 | 11,946 | 1,410 | 5,868 | 0 |
Quality Earnings: LAB B has high quality earnings.
Growing Profit Margin: LAB B's current net profit margins (9.3%) are lower than last year (11.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LAB B's earnings have grown by 6.8% per year over the past 5 years.
Accelerating Growth: LAB B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LAB B had negative earnings growth (-25.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.4%).
Return on Equity
High ROE: LAB B's Return on Equity (13.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/24 15:07 |
| End of Day Share Price | 2026/06/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genomma Lab Internacional, S.A.B. de C.V. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonio Hernandez Velez Leija | Actinver Case de Bolsa, S.A. de C.V. |
| Benjamin Theurer | Barclays |
| Robert Ford Aguilar | BofA Global Research |